Efferon's pediatric sepsis device, a first for children, now in use across 30 countries

Efferon has developed a medical device that it says lowers organ failure rates and significantly accelerates recovery in children with sepsis. When standard treatments like antibiotics cannot stop the immune system's overreaction, a patient's blood must be filtered to remove deadly toxins. That is where Efferon's absorbers, which target dangerous cytokines and toxins, come in.

CEO Dima Romashin compares the body's response during sepsis to a fire. "In a fire, there are two things: the flame itself and smoke that it produces," he told TechCrunch. In sepsis, endotoxins are the flame and cytokines are the smoke. Unlike other devices on the market, Efferon's mechanism can absorb both at once, according to Romashin.

Children have a significantly lower circulating blood volume than adults, so they require medical devices engineered for their physiology. Efferon NEO, the pediatric version, is used in intensive care units across 30 countries, including European hospitals, Saudi Arabia and Thailand. The company is now preparing to file for FDA approval and is on track to hit $2 million in annualized revenue by the end of 2026.

The technology was originally developed by scientists at Moscow State University, including co-founder Ivan Bessonov. Romashin, a serial entrepreneur, stepped in earlier this year as CEO to help commercialize it. He concedes Efferon is not growing at the breakneck pace of today's AI startups, but the company's true measure of success is different: every child who gets to go home.

Analysis

Why This Matters

Sepsis is a leading cause of childhood mortality, claiming roughly 3 million children under five each year, and treatment options designed for children's physiology have been limited.
Efferon NEO is the first multimodal blood purification device engineered specifically for pediatric sepsis, addressing a gap where children's lower blood volume makes adult devices unsuitable.
A planned FDA submission could bring the device to the US market, potentially expanding access to a much larger patient population.

Background

Sepsis is an acute, life-threatening inflammation triggered by infection. When the immune system overreacts, it can damage the body's own organs, and standard treatments such as antibiotics can fail to halt the cascade. In severe cases, clinicians filter a patient's blood to remove the toxins driving the reaction. Children, with smaller bodies and lower circulating blood volume, need devices designed for their physiology, but pediatric-specific options have been scarce. Efferon's technology was originally developed by scientists at Moscow State University, and the company was selected for the Startup Battlefield 200 at TechCrunch Disrupt 2026.

Key Perspectives

Efferon: The company argues its device is a step change because it removes both endotoxins and cytokines, whereas other absorbers on the market target one class of toxin. It points to the CE mark and use across 30 countries as validation. Clinicians and hospitals: Intensive care units in Europe, Saudi Arabia and Thailand have adopted the device, suggesting real demand for pediatric-specific sepsis tools in hospital settings. Critics and skeptics: The device still faces the FDA approval process, and its clinical evidence base has not been detailed in public reporting. At a projected $2 million in annualized revenue, the company remains small, and questions may follow about how quickly regulatory approval translates into widespread adoption.

What to Watch

The timing and outcome of Efferon's FDA submission, and whether US regulators require additional clinical data.
Whether the company hits its $2 million annualized revenue target by the end of 2026.
Published clinical outcomes from hospitals using Efferon NEO, and any expansion into new markets beyond the 30 countries where it is already in use.

Analysis

Why This Matters

Background

Key Perspectives

What to Watch

Sources